Department of Medical Oncology, Medical School, University of Ioannina, Stavros Niarchou Avenue, 45110, Ioannina, Greece.
Drug Development Unit, Sarah Cannon Research Institute, 93 Harley Street, London, W1G 6AD, UK; University College London, London, UK.
Crit Rev Oncol Hematol. 2017 Dec;120:43-51. doi: 10.1016/j.critrevonc.2017.10.007. Epub 2017 Oct 16.
Non-epithelial ovarian cancers (NEOC) constitute a group of uncommon malignancies and their treatment is still a challenging task. Collectively, these tumours account for about 10% of all ovarian cancers and occur in all age groups from childhood to old-age. They include malignancies of germ cell origin, sex cord-stromal cell origin, and a variety of extremely rare ovarian cancers, such as small-cell carcinomas and sarcomas. Each of these classifications encompasses multiple histologic subtypes. It is imperative that these rare tumours are managed with accurate diagnosis, staging, and treatment, to optimise the outcome. The aetiology and molecular origins of each sub-group of NEOC remain largely unresolved, and international cooperation to promote high quality translational research is crucial. Much effort has been made into researching the molecular mechanisms underlying epithelial ovarian cancers, but far less is known about the genetic changes in NEOC. In this article, it is provided an overview of the current knowledge on the incidence, clinical presentation, pathology, genetics, therapeutic interventions, survival and prognostic factors of adult and juvenile granulosa cell tumours (GrCT), Sertoli-Leydig Cell tumours (SLCT) and small cell carcinoma of the ovary. We also consider future potential therapeutic targets in these rare cancers.
非上皮性卵巢癌(NEOC)是一组罕见的恶性肿瘤,其治疗仍然是一项具有挑战性的任务。这些肿瘤共同占所有卵巢癌的 10%左右,发生在从儿童到老年的所有年龄段。它们包括生殖细胞来源、性索-间质细胞来源的恶性肿瘤,以及各种非常罕见的卵巢癌,如小细胞癌和肉瘤。这些分类中的每一种都包含多种组织学亚型。这些罕见肿瘤必须通过准确的诊断、分期和治疗来管理,以优化治疗效果。每个 NEOC 亚组的病因和分子起源在很大程度上仍未得到解决,促进高质量转化研究的国际合作至关重要。人们已经在研究上皮性卵巢癌的分子机制方面做出了很大努力,但对 NEOC 的遗传变化知之甚少。本文概述了成人和青少年颗粒细胞瘤(GrCT)、Sertoli-Leydig 细胞瘤(SLCT)和卵巢小细胞癌的发病率、临床表现、病理学、遗传学、治疗干预、生存和预后因素的最新知识。我们还考虑了这些罕见癌症未来潜在的治疗靶点。